Resource Center
Hard-earned insights that help drug manufacturers achieve their growth, compliance, and profitability objectives
Another Update on Drug Price Disclosure Legislation – Feb 2021
Another Update on Drug Price Disclosure LegislationMore tips for staying compliant with an accelerating trendStates Continue Their March Toward Prescription Drug Transparency Regulations. This paper, our fourth in a series that looks at the rising number of price...
Mergers and Acquisitions Never End In a Tie
Mergers and Acquisitions Never End In A Tie!When it comes to corporate mergers, the acquiring company is almost always the sole beneficiary. The people in the acquired company are, unfortunately, viewed as excess baggage. This displacement of human resources typically...
Have You Been Lulled Into Complacency by a System Based Government Pricing Solution
Have you been lulled into complacency by a system-based government pricing solution?The idea of using a comprehensive, system-based solution for government pricing computations can be appealing. Any tool that promises compliance with complex reporting requirements for...
System Based Calculations Miss Crucial Details In Government Pricing Reports
System-based calculations miss crucial details in government price reporting.When you have complete visibility into the process driving your government pricing computations, you have control. You gain certainty and confidence knowing your monthly and quarterly...
Have Confidence In The Data That Drives Government Pricing Computations
Have confidence in the data that drives government pricing computations.Missed transaction-level details can skew government pricing computations and impact your bottom line by millions of dollars. That’s why it is imperative to have confidence in the data that drives...
Why Medicaid Is a Pharma Company’s Most Demanding Government Program In Terms of Potential Impact and Resources
Why Medicaid is a pharma company’s most demanding government program in terms of potential impact and resources.For both brand and generic pharma companies, the most demanding of the government programs, in terms of financial impact and required resources, is often...
Understanding the complexities of implementing a generic pharmaceutical company commercialization plan.
Understanding the complexities of implementing a generic pharmaceutical company commercialization plan.Seasoned pharma executives know that implementing a generic pharmaceutical company commercialization plan in the US market is a complex exercise in multi-tasking....
Understanding Baseline AMP Rules Can Help You Avoid Pricing Decision Disasters
Understanding Baseline AMP Rules Can Help You Avoid Pricing Decision DisastersWhat brand and generic drug manufacturers need to knowA lack of understanding respective to baseline Average Manufacturer Price (AMP) and how it can affect your Medicaid pricing can result...
Continued Emergence of Drug Price Disclosure Legislation – April 2020
Continued Emergence of Drug Price Disclosure LegislationTips for staying compliant with an accelerating trendStates Have Gotten Aggressive with Fines Against Pharma Companies for Price Reporting Noncompliance This paper, our third in a series that looks at the rising...